Next Article in Journal
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
Previous Article in Journal
Selective Targeting of Cancer Stem Cells (CSCs) Based on Photodynamic Therapy (PDT) Penetration Depth Inhibits Colon Polyp Formation in Mice
Open AccessReview

The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer

1
Department of Pharmacology, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia
2
Divison of Gynecology and Perinatology, University Medical Centre Maribor, 2000 Maribor, Slovenia
3
Department of Obstetrics and Gynecology, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia
4
Department of Pathology, Hospital Graz II, West, 8020 Graz, Austria
5
Department of Pathology, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia
6
Department of Pathology, Medical Faculty Otto-von-Guericke University Magdeburg, 39120 Magdeburg, Germany
7
Department of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, 6020 Innsbruck, Austria
8
Diagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 205; https://doi.org/10.3390/cancers12010205
Received: 8 November 2019 / Revised: 4 January 2020 / Accepted: 10 January 2020 / Published: 14 January 2020
(This article belongs to the Special Issue Close links between Cold Shock Proteins and Cancer)
Studies of the mechanistic (mammalian) target of rapamycin inhibitors (mTOR) represent a step towards the targeted treatment of gynecological cancers. It has been shown that women with increased levels of mTOR signaling pathway targets have worse prognosis compared to women with normal mTOR levels. Yet, targeting mTOR alone has led to unsatisfactory outcomes in gynecological cancer. The aim of our review was therefore to provide an overview of the most recent clinical results and basic findings on the interplay of mTOR signaling and cold shock proteins in gynecological malignancies. Due to their oncogenic activity, there are promising data showing that mTOR and Y-box-protein 1 (YB-1) dual targeting improves the inhibition of carcinogenic activity. Although several components differentially expressed in patients with ovarian, endometrial, and cervical cancer of the mTOR were identified, there are only a few investigated downstream actors in gynecological cancer connecting them with YB-1. Our analysis shows that YB-1 is an important player impacting AKT as well as the downstream actors interacting with mTOR such as epidermal growth factor receptor (EGFR), Snail or E-cadherin. View Full-Text
Keywords: mTOR signaling; YB-1; endometrial cancer; ovarian cancer; cervical cancer mTOR signaling; YB-1; endometrial cancer; ovarian cancer; cervical cancer
Show Figures

Figure 1

MDPI and ACS Style

Sobočan, M.; Bračič, S.; Knez, J.; Takač, I.; Haybaeck, J. The Communication between the PI3K/AKT/mTOR Pathway and Y-Box Binding Protein-1 in Gynecological Cancer. Cancers 2020, 12, 205.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop